Dublin, Ireland, 19 July 2022: Afimmune, a privately held, clinical stage biopharmaceutical company, today announced that the Food and Drug Administration (FDA) in the United States […]
Dublin, Ireland, 10 June 2022: Afimmune, a privately held, clinical stage biopharmaceutical company, today announced that results of its investigational drug Epeleuton will be presented at […]
Presentation during EHA2022: All (e)Poster presentations will be made available as of Friday, June 10, 2022 (09:00 CEST) and will be accessible for on-demand viewing until […]
Epeleuton decreases viral titres and SARS-CoV-2 RNA and histopathological damage in the upper and lower respiratory tract Dublin, Ireland, 26th August 2021 – Afimmune, a clinical stage drug discovery […]
Data show large decreases in atherosclerotic plaque following treatment with epeleuton Dublin, Ireland, 3rd June 2021 – Afimmune, a clinical stage drug discovery company focused on […]
Dublin, Ireland, 18th December 2018 – Afimmune, a privately held clinical stage drug discovery and development company, today announced receipt of allowance for a patent application in […]
Dublin, Ireland, 18th October 2017 – Afimmune (AF), a privately held drug discovery and development company, today announced receipt of allowance for a patent application in […]
Dublin, Ireland, December 18th, 2015 – Afimmune, a privately held biopharmaceutical company, today announced the successful completion of a Phase I trial with an oral formulation […]
